Management options for metastatic melanoma in the era of novel therapies: a primer for the practicing dermatologist: part II: Management of stage IV disease.

Fox, Matthew C; Lao, Christopher D; Schwartz, Jennifer L; Frohm, Marcus L; Bichakjian, Christopher K; Johnson, Timothy M

Fox, Matthew C; Lao, Christopher D; Schwartz, Jennifer L; Frohm, Marcus L; Bichakjian, Christopher K; Johnson, Timothy M.

Affiliation

Fox MC; Department of Dermatology, University of Michigan Medical School and Comprehensive Cancer Center, Ann Arbor, Michigan, USA. matfox@med.umich.edu

J Am Acad Dermatol ; 68(1): 13.e1-13; quiz 26-8, 2013 Jan.

Article in En | MEDLINE | ID: mdl-23244384

Subject(s)

Brain Neoplasms/secondary; Brain Neoplasms/therapy; Melanoma/secondary; Melanoma/therapy; Palliative Care; Skin Neoplasms/pathology; Skin Neoplasms/therapy; Antibodies, Monoclonal/therapeutic use; Antineoplastic Agents/therapeutic use; Dacarbazine/therapeutic use; Humans; Immunologic Factors/therapeutic use; Indoles/therapeutic use; Interleukin-2/therapeutic use; Ipilimumab; Neoplasm Staging; Protein-Tyrosine Kinases/antagonists & inhibitors; Proto-Oncogene Proteins c-kit/genetics; Radiosurgery; Sulfonamides/therapeutic use; Vemurafenib; raf Kinases/antagonists & inhibitors

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Palliative Care / Skin Neoplasms / Brain Neoplasms / Melanoma Type of study: Guideline Limits: Humans Language: En Journal: J Am Acad Dermatol Year: 2013 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google